Eboni I Lance1,2, Emily Barron-Casella3, Allen D Everett4, James F Casella3. 1. Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland. 2. Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Pediatrics, Division of Hematology, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Department of Pediatrics, Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: Children with sickle cell disease (SCD) have an increased risk of neurological complications, particularly stroke and silent cerebral infarction (SCI). Brain-derived neurotrophic factor (BDNF) is a nerve growth factor associated with neuronal survival, synaptic plasticity, elevated transcranial Doppler (TCD) velocities and increased risk of stroke in patients with SCD. The objective of this study was to analyze plasma BDNF protein levels in children with SCD participating in the Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial (SIT Trial), comparing plasma samples of children with SCD and SCI to plasma samples from children with SCD without SCI, as well as healthy pediatric control participants. PROCEDURE: Entry, exit, and longitudinal blood samples were collected from 190 SIT Trial participants with SCD and healthy pediatric controls over time. BDNF levels were measured by enzyme-linked immunosorbent assay. Sample collection was not optimized for measurements of BDNF, but factors affecting BDNF levels were accounted for in analyses. RESULTS: BDNF levels were significantly higher in children with SCD in comparison to healthy pediatric control subjects. BDNF levels significantly increased over time in SCD participants. BDNF levels did not show any significant associations with the presence or absence of SCI or new/progressive SCI/stroke or TCD velocities. CONCLUSIONS: Plasma BDNF levels are elevated and increase over time in children with SCD. Additional studies with more longitudinal samples are needed to address the reasons for those increased levels.
BACKGROUND:Children with sickle cell disease (SCD) have an increased risk of neurological complications, particularly stroke and silent cerebral infarction (SCI). Brain-derived neurotrophic factor (BDNF) is a nerve growth factor associated with neuronal survival, synaptic plasticity, elevated transcranial Doppler (TCD) velocities and increased risk of stroke in patients with SCD. The objective of this study was to analyze plasma BDNF protein levels in children with SCD participating in the Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial (SIT Trial), comparing plasma samples of children with SCD and SCI to plasma samples from children with SCD without SCI, as well as healthy pediatric control participants. PROCEDURE: Entry, exit, and longitudinal blood samples were collected from 190 SIT Trial participants with SCD and healthy pediatric controls over time. BDNF levels were measured by enzyme-linked immunosorbent assay. Sample collection was not optimized for measurements of BDNF, but factors affecting BDNF levels were accounted for in analyses. RESULTS:BDNF levels were significantly higher in children with SCD in comparison to healthy pediatric control subjects. BDNF levels significantly increased over time in SCDparticipants. BDNF levels did not show any significant associations with the presence or absence of SCI or new/progressive SCI/stroke or TCD velocities. CONCLUSIONS: Plasma BDNF levels are elevated and increase over time in children with SCD. Additional studies with more longitudinal samples are needed to address the reasons for those increased levels.
Authors: Michael R DeBaun; Mae Gordon; Robert C McKinstry; Michael J Noetzel; Desiree A White; Sharada A Sarnaik; Emily R Meier; Thomas H Howard; Suvankar Majumdar; Baba P D Inusa; Paul T Telfer; Melanie Kirby-Allen; Timothy L McCavit; Annie Kamdem; Gladstone Airewele; Gerald M Woods; Brian Berman; Julie A Panepinto; Beng R Fuh; Janet L Kwiatkowski; Allison A King; Jason M Fixler; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Natalia Dixon; Corina E Gonzalez; Karen A Kalinyak; Charles T Quinn; John J Strouse; J Philip Miller; Harold Lehmann; Michael A Kraut; William S Ball; Deborah Hirtz; James F Casella Journal: N Engl J Med Date: 2014-08-21 Impact factor: 91.245
Authors: James F Casella; Allison A King; Bruce Barton; Desiree A White; Michael J Noetzel; Rebecca N Ichord; Cindy Terrill; Deborah Hirtz; Robert C McKinstry; John J Strouse; Thomas H Howard; Thomas D Coates; Caterina P Minniti; Andrew D Campbell; Bruce A Vendt; Harold Lehmann; Michael R Debaun Journal: Pediatr Hematol Oncol Date: 2010-03 Impact factor: 1.969
Authors: Michael R DeBaun; Sharada A Sarnaik; Mark J Rodeghier; Caterina P Minniti; Thomas H Howard; Rathi V Iyer; Baba Inusa; Paul T Telfer; Melanie Kirby-Allen; Charles T Quinn; Françoise Bernaudin; Gladstone Airewele; Gerald M Woods; Julie Ann Panepinto; Beng Fuh; Janet K Kwiatkowski; Allison A King; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Hernan Sabio; Corina E Gonzalez; Suzanne L Saccente; Karen A Kalinyak; John J Strouse; Jason M Fixler; Mae O Gordon; J Phillip Miller; Michael J Noetzel; Rebecca N Ichord; James F Casella Journal: Blood Date: 2011-11-17 Impact factor: 22.113
Authors: Niklas Mattsson; Maria C Carrillo; Robert A Dean; Michael D Devous; Tania Nikolcheva; Pedro Pesini; Hugh Salter; William Z Potter; Reisa S Sperling; Randall J Bateman; Lisa J Bain; Enchi Liu Journal: Alzheimers Dement (Amst) Date: 2015-10-03
Authors: Russell E Ware; Barry R Davis; William H Schultz; R Clark Brown; Banu Aygun; Sharada Sarnaik; Isaac Odame; Beng Fuh; Alex George; William Owen; Lori Luchtman-Jones; Zora R Rogers; Lee Hilliard; Cynthia Gauger; Connie Piccone; Margaret T Lee; Janet L Kwiatkowski; Sherron Jackson; Scott T Miller; Carla Roberts; Matthew M Heeney; Theodosia A Kalfa; Stephen Nelson; Hamayun Imran; Kerri Nottage; Ofelia Alvarez; Melissa Rhodes; Alexis A Thompson; Jennifer A Rothman; Kathleen J Helton; Donna Roberts; Jamie Coleman; Melanie J Bonner; Abdullah Kutlar; Niren Patel; John Wood; Linda Piller; Peng Wei; Judy Luden; Nicole A Mortier; Susan E Stuber; Naomi L C Luban; Alan R Cohen; Sara Pressel; Robert J Adams Journal: Lancet Date: 2015-12-06 Impact factor: 79.321
Authors: Eboni I Lance; Lisa M Faulcon; Zongming Fu; Jun Yang; Donna Whyte-Stewart; John J Strouse; Emily Barron-Casella; Kimberly Jones; Jennifer E Van Eyk; James F Casella; Allen D Everett Journal: Proteomics Clin Appl Date: 2021-05-24 Impact factor: 3.603
Authors: Christopher Chambliss; Tatayana Richardson; John Onyekaba; Juan Cespedes; Annette Nti; Keri Oxendine Harp; Iris Buchanan-Perry; Jonathan K Stiles; Beatrice E Gee Journal: Endocr Metab Sci Date: 2021-02-14